
MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 894 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS inhibitor-38
CAS:KRAS Inhibitor-38 (Example 18) is a potent inhibitor capable of effectively suppressing the activity of KRAS G12C, KRAS G12D, and KRAS G12V in vivo.Fórmula:C53H68ClF2N9O8SCor e Forma:SolidPeso molecular:1064.68MC 976
CAS:MC 976 is a derivative of Vitamin D3.Fórmula:C27H42O3Pureza:98%Cor e Forma:SolidPeso molecular:414.63PDE4-IN-26
PDE4-IN-26 (Compound A5) is an orally active, highly selective inhibitor of PDE4. It exhibits anti-inflammatory properties by inhibiting p38 MAPK phosphorylation. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 reduces lung inflammation, damage, and fibrosis, while promoting sputum secretion and alleviating cough. It is useful for researching lung injury-related diseases.Fórmula:C22H18F2N4O3SCor e Forma:SolidPeso molecular:456.47NUCC-0200808
NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.Cor e Forma:Odour SolidKRAS G12D inhibitor 6
CAS:<p>KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.</p>Fórmula:C32H37ClN8O2Cor e Forma:SolidPeso molecular:601.15Z16078526
CAS:Z16078526 promotes Ucp1, p38 MAPK, lipolysis, thermogenic genes, and mitochondrial activity in mouse brown adipocytes.Fórmula:C18H17N3O4SPureza:99.18%Cor e Forma:SolidPeso molecular:371.41MEK/RAF-IN-1
MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.Fórmula:C28H29F3N6O5SCor e Forma:SolidPeso molecular:618.63Setidegrasib
CAS:KRAS G12D inhibitor 17, a quinazoline-linked prolinamide, degrades mutant KRAS protein; a PROTAC.Fórmula:C60H65FN12O7SCor e Forma:SolidPeso molecular:1117.3Rac1 Inhibitor W56
CAS:Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.Fórmula:C74H117N19O23SPureza:98%Cor e Forma:SolidPeso molecular:1671.93NecroX-2
CAS:NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Fórmula:C25H32N4O4S2Pureza:97.12%Cor e Forma:SolidPeso molecular:516.68LYMTAC-2
LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.Cor e Forma:SolidPeso molecular:1248.44FAM49B (190-198) mouse
CAS:FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.Fórmula:C49H71N9O14SCor e Forma:SolidPeso molecular:1042.2KG5
CAS:<p>KG5 inhibits PDGFRβ, B-Raf, FLT3, KIT, c-Raf; has anticancer and antiangiogenic effects; Kd: 520 nM (PDGFRβ), 300 nM (PDGFRα).</p>Fórmula:C20H16F3N7OSPureza:98.32%Cor e Forma:SolidPeso molecular:459.45BAS 00489700
CAS:BAS 00489700 is a N-UTR interaction inhibitor. BAS 00489700 inhibits virus replication in cell culture.Fórmula:C19H16N2O4Pureza:99.78%Cor e Forma:SolidPeso molecular:336.34Antimicrobial agent-21
CAS:Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment ofFórmula:C18H13N3OSPureza:99.82%Cor e Forma:SolidPeso molecular:319.38Klotho-derived peptide 1 hydrochloride
Klotho-derived peptide 1 (KP1 human) hydrochloride inhibits the interaction between TGF-β and TGF-β receptor 2, suppressing the activation of TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK). Additionally, it exhibits antifibrotic and renal protective effects in mouse models.Cor e Forma:Odour Solid12-Oxo phytodienoic acid
CAS:<p>12-oxo PDA boosts alkaloid production in E. californica, enhances B. dioica tendril curls, and blocks JA-induced cell death in A. fru mutants.</p>Fórmula:C18H28O3Pureza:98%Cor e Forma:SolidPeso molecular:292.41Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidMAPK Inhibitor Library
A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;Cor e Forma:Odour SolidDS03090629
DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.Fórmula:C25H26ClN5O2Cor e Forma:SolidPeso molecular:463.96

